Algorae Pharmaceuticals Ltd

Algorae Pharmaceuticals operates with a capital structure characterized by a high price-to-book ratio of 12.71, indicating a significant premium on equity relative to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, reflecting a conservative leverage profile. Its liquidity position is strong, with a current ratio of 14.13, suggesting ample short-term assets to cover liabilities. However, negative operating and free cash flows of -785,250 AUD and -802,960 AUD, respectively, highlight ongoing cash burn. Profitability metrics are negative, with a return on equity (ROE) of -36.03% and return on assets (ROA) of -33.48%, both significantly below the industry median for biotechnology firms. These figures indicate that the company is not generating returns on its equity or asset base, consistent with its pre-revenue, R&D-focused business model. Operating income of -1,555,460 AUD and net income of -802,960 AUD underscore the substantial losses incurred in the latest reporting period. The company’s revenue of 141,050 AUD is derived from undisclosed sources, as no segment or geographic breakdown is provided in the input data. Given the absence of revenue concentration details, it is unclear whether the company has diversified revenue streams or is reliant on a single market or product. The lack of segment reporting limits visibility into geographic exposure and business diversification. Growth trajectory is speculative, with no disclosed revenue growth rates or forward-looking guidance. The company’s outlook for the current and next fiscal years is not quantified, but its ongoing losses and negative cash flows suggest a continuation of R&D investment over near-term revenue generation. The absence of a clear path to profitability or product commercialization introduces uncertainty around future growth. Risk factors include high liquidity risk due to negative operating cash flows and a lack of near-term revenue-generating assets. While dilution risk is currently low, the company’s market cap of 28.3 million AUD and high price-to-book ratio suggest potential for future equity issuance to fund operations. No immediate filing-based dilution or liquidity flags were detected, but the absence of long-term debt does not mitigate the risk of equity dilution in the event of capital calls. Recent events include the continued development of AI-116, AI-168, and NTCELL, with no disclosed regulatory milestones or clinical trial updates in the input data. The company’s reliance on AI-driven drug discovery remains a core strategic focus, but the absence of recent filings or transcripts limits insight into operational progress or management commentary.